Fundraising Fox
/Companies
Sign in

Omeicos Therapeutics

Berlin, DE · Founded 2013 · 9 employees on LinkedIn · 3 known investors

Find your way into Omeicos Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

19 people can intro you to Robert

Ask Ute Mercker to introduce you to Robert Fischer

You →Ute · together at Omeicos Therapeutics →Robert

3 people can intro you to Karen

Ask Jamie Chen to introduce you to Karen Uhlmann

You →Jamie · together at Omeicos Therapeutics →Karen

Sign up to find every way you can get introduced to Omeicos Therapeutics

  • Your email: who you already know at Omeicos Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Omeicos Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.

BiotechHealthtech

Founders & leadership

Omeicos Therapeutics was founded in 2013 by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, and John R. Falck.

RF
Robert FischerCEO/CSO & Co-FounderRobert Fischer is CEO and Chief Scientific Officer of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular and mitochondrial diseases. He has expertise in cardiology and cardiac arrhythmias, holds board certification in internal medicine, and has authored over 20 publications and contributed to 2 patents.
KUKaren Uhlmann
Karen UhlmannVice President Operations & IP, Co-FounderKaren Uhlmann is Vice President of Operations & IP and Co-Founder of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular, inflammatory, and rare mitochondrial diseases. She has experience in technology transfer and serves as an expert advisor for research funding and startup evaluation bodies in Europe.
WS
Wolf-Hagen SchunckCo-Founder
JR
John R. FalckCo-Founder

Investors · 3

Forbion✓ confirmed by Omeicos TherapeuticsNaarden

How we know: the company's own site · a partner's Signal profile · funding news · Not right? Tell us

Vesalius Biocapital Partnerslisted by Vesalius Biocapital PartnersLuxembourg · $11M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Omeicos Therapeutics do?
OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.
Who founded Omeicos Therapeutics?
Omeicos Therapeutics was founded by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, John R. Falck in 2013.
Who are Omeicos Therapeutics's investors?
Omeicos Therapeutics's investors include Remiges Ventures, Inc., Forbion, Vesalius Biocapital Partners.
Where is Omeicos Therapeutics headquartered?
Omeicos Therapeutics is headquartered in Berlin, DE.